These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 19446662)

  • 21. Regulation of osteoblast differentiation by slit2 in osteoblastic cells.
    Sun H; Dai K; Tang T; Zhang X
    Cells Tissues Organs; 2009; 190(2):69-80. PubMed ID: 19033678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TNFalpha promotes osteogenic differentiation of human mesenchymal stem cells by triggering the NF-kappaB signaling pathway.
    Hess K; Ushmorov A; Fiedler J; Brenner RE; Wirth T
    Bone; 2009 Aug; 45(2):367-76. PubMed ID: 19414075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteoblast function in myeloma.
    Roodman GD
    Bone; 2011 Jan; 48(1):135-40. PubMed ID: 20601285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
    Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
    Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment.
    Giuliani N; Morandi F; Tagliaferri S; Lazzaretti M; Donofrio G; Bonomini S; Sala R; Mangoni M; Rizzoli V
    Cancer Res; 2007 Aug; 67(16):7665-74. PubMed ID: 17702698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adiponectin stimulates osteoblast differentiation through induction of COX2 in mesenchymal progenitor cells.
    Lee HW; Kim SY; Kim AY; Lee EJ; Choi JY; Kim JB
    Stem Cells; 2009 Sep; 27(9):2254-62. PubMed ID: 19522015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Wnt signaling controls the fate of mesenchymal stem cells.
    Ling L; Nurcombe V; Cool SM
    Gene; 2009 Mar; 433(1-2):1-7. PubMed ID: 19135507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells.
    Silvestris F; Cafforio P; Calvani N; Dammacco F
    Br J Haematol; 2004 Aug; 126(4):475-86. PubMed ID: 15287939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Wnt and steroid pathways control glutamate signalling by regulating glutamine synthetase activity in osteoblastic cells.
    Olkku A; Mahonen A
    Bone; 2008 Sep; 43(3):483-93. PubMed ID: 18555765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The osteoblastic niche in the context of multiple myeloma.
    Toscani D; Bolzoni M; Accardi F; Aversa F; Giuliani N
    Ann N Y Acad Sci; 2015 Jan; 1335():45-62. PubMed ID: 25424768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic modifications in osteogenic differentiation and transformation.
    Thomas D; Kansara M
    J Cell Biochem; 2006 Jul; 98(4):757-69. PubMed ID: 16598744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathophysiology of multiple myeloma bone disease.
    Lentzsch S; Ehrlich LA; Roodman GD
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1035-49, viii. PubMed ID: 17996587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Wnt inhibitors and the suppression of bone formation in multiple myeloma].
    Abe M
    Clin Calcium; 2013 Jun; 23(6):867-75. PubMed ID: 23719500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ghrelin inhibits early osteogenic differentiation of C3H10T1/2 cells by suppressing Runx2 expression and enhancing PPARgamma and C/EBPalpha expression.
    Kim SW; Choi OK; Jung JY; Yang JY; Cho SW; Shin CS; Park KS; Kim SY
    J Cell Biochem; 2009 Mar; 106(4):626-32. PubMed ID: 19160422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment strategies for bone disease.
    Roodman GD
    Bone Marrow Transplant; 2007 Dec; 40(12):1139-46. PubMed ID: 17680018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surface nanofeature effects on titanium-adherent human mesenchymal stem cells.
    Valencia S; Gretzer C; Cooper LF
    Int J Oral Maxillofac Implants; 2009; 24(1):38-46. PubMed ID: 19344023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myeloma bone disease: pathogenetic mechanisms and clinical assessment.
    Silvestris F; Lombardi L; De Matteo M; Bruno A; Dammacco F
    Leuk Res; 2007 Feb; 31(2):129-38. PubMed ID: 16764925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Signalling and survival pathways in multiple myeloma.
    Bommert K; Bargou RC; Stühmer T
    Eur J Cancer; 2006 Jul; 42(11):1574-80. PubMed ID: 16797970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The bone marrow stromal compartment in multiple myeloma patients retains capability for osteogenic differentiation in vitro: defining the stromal defect in myeloma.
    Kassen D; Moore S; Percy L; Herledan G; Bounds D; Rodriguez-Justo M; Croucher P; Yong K
    Br J Haematol; 2014 Oct; 167(2):194-206. PubMed ID: 25079197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanotransduction in osteoblast regulation and bone disease.
    Papachroni KK; Karatzas DN; Papavassiliou KA; Basdra EK; Papavassiliou AG
    Trends Mol Med; 2009 May; 15(5):208-16. PubMed ID: 19362057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.